Table 1.
Patient and transplant characteristics.
| MRD negative | MRD positive | Test p-value | |
|---|---|---|---|
| Number | 749 | 293 | |
| Follow-up (surviving patients): median (range) (IQR) | 24.6 (0.5–132.5) (7.7–54.3) | 26.9 (0.8–121.5) (8.2–60.4) | 0.58 |
| Age at transplant: median (range) (IQR) | 49.4 (18–78.1) (37.7–58.8) | 49.8 (19.5–72.9) (37.6–58.4) | 0.89 |
| Year of transplant: median (range) | 2012 (2006–2016) | 2012 (2006–2016) | 0.31 |
| Time from diagnosis to transplant: median (range) (IQR) m | 18.2 (3–200) (13.5–27.1) | 15.9 (3–200) (11.6–21.8) | <10−4 |
| Male patients | 390 (52.07%) | 168 (57.34%) | 0.13 |
| Female patients | 359 (47.93%) | 125 (42.66%) | |
| Donor male | 445 (60.22%) | 189 (64.73%) | 0.18 |
| Donor female | 294 (39.78%) | 103 (35.27%) | |
| Missing | 10 | 1 | |
| Female recipients and male recipients of male donors | 598 (80.27%) | 243 (83.22%) | 0.28 |
| Male recipients of female donors | 147 (19.73%) | 49 (16.78%) | |
| Missing | 4 | 1 | |
| KPS < 80 | 25 (3.49%) | 8 (2.86%) | 0.62 |
| KPS > = 80 | 691 (96.51%) | 272 (97.14%) | |
| missing | 33 | 13 | |
| KPS < 90 | 148 (21.08%) | 63 (22.74%) | 0.57 |
| KPS > = 90 | 554 (78.92%) | 214 (77.26%) | |
| Missing | 47 | 16 | |
| Patient CMV negative | 248 (34.35%) | 95 (32.76%) | 0.63 |
| Patient CMV positive | 474 (65.65%) | 195 (67.24%) | |
| Missing | 27 | 3 | |
| Donor CMV negative | 331 (45.84%) | 146 (51.59%) | 0.10 |
| Donor CMV positive | 391 (54.16%) | 137 (48.41%) | |
| Missing | 27 | 10 | |
| CMV donor negative/recipient negative | 177 (24.96%) | 71 (25.18%) | 0.24 |
| CMV donor positive/recipient negative | 66 (9.31%) | 23 (8.16%) | |
| CMV donor negative/recipient positive | 146 (20.59%) | 74 (26.24%) | |
| CMV donor positive/recipient positive | 320 (45.13%) | 114 (40.43%) | |
| Missing | 40 | 11 | |
| Cytogenetics | |||
| Good | 193 (48.61%) | 102 (53.4%) | 0.18 |
| Intermediate | 188 (47.36%) | 77 (40.31%) | |
| Adverse | 16 (4.03%) | 12 (6.28%) | |
| Missing | 352 | 102 | |
| FLT3 negative | 94 (63.09%) | 66 (70.21%) | 0.25 |
| FLT3 positive | 55 (36.91%) | 28 (29.79%) | |
| Missing | 600 | 199 | |
| NPM1 negative | 42 (33.6%) | 31 (42.47%) | 0.21 |
| NPM1 positive | 83 (66.4%) | 42 (57.53%) | |
| Missing | 624 | 220 | |
| MSD | 376 (50.2%) | 134 (45.73%) | 0.20 |
| VUD HLA 10/10 | 373 (49.8%) | 159 (54.27%) | |
| MAC | 430 (57.41%) | 180 (61.43%) | 0.24 |
| RIC | 319 (42.59%) | 113 (38.57%) | |
CMV cytomegalovirus, IQR interquartile range, KPS Karnofsky performance status, MAC myeloablative conditioning, MSD matched sibling donor, RIC reduced-intensity conditioning, MUD matched unrelated donor.